Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis-Reference-Cited by-同舟云学术

Long-Term Decrease in VLA-4 Expression and Functional Impairment of Dendritic Cells during Natalizumab Therapy in Patients with Multiple Sclerosis

Published:2012-04-04 Issue:4 Volume:7 Page:e34103
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

de Andrés Clara,Teijeiro Roseta,Alonso Bárbara,Sánchez-Madrid Francisco,Martínez M. Luisa,de Villoria Juan Guzmán,Fernández-Cruz Eduardo,Sánchez-Ramón Silvia

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.;C Lucchinetti;Ann Neurol,2000

2. Multiple sclerosis.;DA Hafler;Immunol Rev,2005

3. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells.;B Serafini;J Neuropathol Exp Neurol,2006

4. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis.;M Stasiolek;Brain,2006

5. Altered maturation of circulating dendritic cells in primary progressive MS patients.;C López;J Neuroimmunol,2006

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics;International Journal of Molecular Sciences;2024-07-04

2. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study;Neurotherapeutics;2024-07

3. Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis;Journal of Neuroimmunology;2024-05

4. Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review;Current Pharmaceutical Design;2024-02

5. Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs;Clinical Immunology Communications;2023-12